{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:22:21Z","timestamp":1773282141928,"version":"3.50.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1097\/ico.0b013e31815cf67d","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T16:54:47Z","timestamp":1236272087000},"page":"349-352","source":"Crossref","is-referenced-by-count":46,"title":["Inhibition of Experimental Corneal Neovascularization by Using Subconjunctival Injection of Bevacizumab (Avastin)"],"prefix":"10.1097","volume":"27","author":[{"given":"Tae-im","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunwoong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eung Kweon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-19-20210204","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/10454411950060030501","article-title":"The pathophysiology of angiogenesis.","volume":"6","author":"Polverini","year":"1995","journal-title":"Crit Rev Oral Biol Med"},{"key":"R2-19-20210204","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00003226-198706040-00004","article-title":"Corneal neovascularization pathogenesis and inhibition.","volume":"6","author":"Epstein","year":"1987","journal-title":"Cornea"},{"key":"R3-19-20210204","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00417-007-0542-4","article-title":"Inhibition of corneal angiogenesis by ascorbic acid in the rat model.","volume":"245","author":"Peyman","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R4-19-20210204","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/0002-9394(68)90821-0","article-title":"Prevention of corneal vascularization.","volume":"66","author":"Ey","year":"1968","journal-title":"Am J Ophthalmol"},{"key":"R5-19-20210204","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ajo.2006.10.004","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.","volume":"143","author":"Chen","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R6-19-20210204","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R7-19-20210204","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/bjo.2006.107417","article-title":"Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier.","volume":"91","author":"Ambati","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R8-19-20210204","first-page":"4593","article-title":"Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders.","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"R9-19-20210204","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"R11-19-20210204","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ajo.2006.06.066","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.","volume":"142","author":"Iliev","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R12-19-20210204","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/lsm.1900170207","article-title":"In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization.","volume":"17","author":"Schmidt-Erfurth","year":"1995","journal-title":"Lasers Surg Med"},{"key":"R13-19-20210204","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nrc909","article-title":"VEGF and the quest for tumour angiogenesis factors.","volume":"2","author":"Ferrara","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"R14-19-20210204","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen.","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"R15-19-20210204","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.","volume":"20","author":"Dvorak","year":"2002","journal-title":"J Clin Oncol"},{"key":"R16-19-20210204","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"R17-19-20210204","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/019262339902700507","article-title":"Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.","volume":"27","author":"Mordenti","year":"1999","journal-title":"Toxicol Pathol"},{"key":"R18-19-20210204","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1158\/1078-0432.CCR-03-0605","article-title":"Cancer and Leukemia Group B. Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.","volume":"10","author":"Rini","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R19-19-20210204","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study.","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"R20-19-20210204","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00006982-200603000-00001","article-title":"Testing intravitreal toxicity of bevacizumab (Avastin).","volume":"26","author":"Manzano","year":"2006","journal-title":"Retina"},{"key":"R21-19-20210204","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab (Avastin) therapy for corneal neovascularization.","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R22-19-20210204","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3565(24)37962-5","article-title":"Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.","volume":"288","author":"Lin","year":"1999","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003226-200804000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T01:30:24Z","timestamp":1738978224000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-200804000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e31815cf67d","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}